18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
about
Towards multidimensional radiotherapy: key challenges for treatment individualisation.Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomographyLymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic ResponseA semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT.Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancerPrediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer.Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.(18)F Sodium Fluoride PET/CT in Patients with Prostate Cancer: Quantification of Normal Tissues, Benign Degenerative Lesions, and Malignant LesionsA preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapyRepeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation.A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment.PET/CT in therapy evaluation of patients with lung cancer.Image-derived biomarkers and multimodal imaging strategies for lung cancer management.The role of PET-CT in radiotherapy planning of solid tumours.Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy.PET in the management of locally advanced and metastatic NSCLC.Present and future roles of FDG-PET/CT imaging in the management of lung cancer.FDG and Beyond.Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review.Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSQuantitative differences in [(18)F] NaF PET/CT: TOF versus non-TOF measurements.Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients.Impact of moving target on measurement accuracy in 3D and 4D PET imaging-a phantom study.Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.Impact of CT attenuation correction method on quantitative respiratory-correlated (4D) PET/CT imaging.Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy.Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT.
P2860
Q27687218-19F6B1A0-9CD6-4999-866D-2AC728D5038FQ28540769-5400831F-3731-4426-AB64-99B9DB48F3E6Q33584618-E311FCD2-ADB1-4D00-ABF1-0C5343971F9AQ33904549-272C68BB-A0CD-4985-B248-23382B86FBC0Q34097425-E29EAB0D-6C3B-44A4-B4BB-5303B6842C60Q34175770-986C1463-D14B-40DA-83A3-85307BFAC7B8Q34724752-6F558127-10E7-4B76-841D-AF4C9E6148D0Q34810709-833DDC21-19B8-4F0C-A9ED-1411BB0B73CBQ36056706-16D66AA2-AD46-42D3-B17D-A90A9758CE11Q36093008-03B72B13-57DB-4F6E-B188-BBCE7D297699Q36288418-ADF44675-388E-4663-BC05-B9202865BECCQ36427037-D5D2165E-5A83-4D5A-917F-E7DCCE4D8CDBQ36733087-C9BA293E-93B2-45DC-BAEF-74081655EA51Q37136741-6AEDA0E5-FBC3-45DA-9E47-D4D10DED9D62Q37230607-989E5DD2-4521-4809-AEE3-B06E8A7B2713Q37594914-1A3A9A14-EF7A-4169-A067-C81D18A4F7A0Q37687711-DE08C7DD-45F4-4428-A9E6-9A27AC3347F1Q38202189-9D23463D-DDFB-42D6-969B-5D351132A9BEQ38312373-BA3E4A70-2683-4BE9-BB95-4526B06CAA51Q38391624-7E909694-30A1-45E8-A0E0-63BC22DE727EQ38401906-E222DD8D-FA70-42C0-B68D-7FD6A9C1F428Q38444980-FE7F89CC-954E-435E-AB4D-6DCE87DEBF5BQ38819166-3AB4E2C7-CACA-4285-9701-3D2715C09257Q38869438-1E9BDC60-DAFF-492E-A04D-3CD07A728C08Q39051286-AB8AA150-16EA-497D-B3F7-1F10CD7FD997Q39417217-85C7C28E-655F-4871-AE81-298873C57934Q40200536-B650930E-B2DF-499A-BE6B-401FA283455BQ40342130-107F1650-AE95-4FF3-8A86-CB26402F3355Q40418227-06B6381E-985B-40B5-99F8-97C237380EA9Q41039688-ADB6F788-12C8-41FE-BE7D-BC0FC3B2D408Q41555630-55D2E77E-8829-4696-8711-803F95BD88CCQ42355410-547B980E-E37A-4229-8B65-6628B71023AAQ47718840-0B2FF9F6-B327-45F5-B16C-06AA5BB927B5Q47898194-72C935EA-F307-416E-82D6-3E6E7C342D39Q52983320-3B294C40-DBF4-4733-AA69-3D06A7FF43F4Q52992671-8B57DDB2-7E10-400A-BBE1-C9BB5A2F08F7
P2860
18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@en
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@nl
type
label
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@en
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@nl
prefLabel
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@en
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@nl
P2093
P50
P1476
18F-FDG PET early response eva ...... concomitant chemoradiotherapy.
@en
P2093
Erik H F M van der Heijden
Esther G C Troost
Johannes H A M Kaanders
Liesbeth Peters-Bax
Olga C J Schuurbiers
P304
P356
10.2967/JNUMED.112.116921
P407
P577
2013-07-17T00:00:00Z